Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]C. E. DeSantis, R. L. Siegel, A. G. Sauer, K. D. Miller, S. A. Fedewa, K. I. Alcaraz and A. Jemal: Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin, 66(4), 290-308 (2016)

  • [2]O. Bratt, A. Borg, U. Kristoffersson, R. Lundgren, Q. X. Zhang and H. Olsson: CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer, 81(4), 672-6 (1999)

  • [3]C. L. Bennett, D. K. Price, S. Kim, D. Liu, B. D. Jovanovic, D. Nathan, M. E. Johnson, J. S. Montgomery, K. Cude, J. C. Brockbank, O. Sartor and W. D. Figg: Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol, 20(17), 3599-604 (2002)

  • [4]K. A. Nelson and J. S. Witte: Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol, 155(10), 883-90 (2002)

  • [5]D. Feldman: Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. J Natl Cancer Inst, 89(2), 109-11 (1997)

  • [6]G. A. Coetzee and R. K. Ross: Re: Prostate cancer and the androgen receptor. J Natl Cancer Inst, 86(11), 872-3 (1994)

  • [7]D. O. Hardy, H. I. Scher, T. Bogenreider, P. Sabbatini, Z. F. Zhang, D. M. Nanus and J. F. Catterall: Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab, 81(12), 4400-5 (1996)

  • [8]K. Mir, J. Edwards, P. J. Paterson, M. Hehir, M. A. Underwood and J. M. Bartlett: The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer. BJU Int, 90(6), 573-8 (2002)

  • [9]D. K. Price, C. H. Chau, C. Till, P. J. Goodman, C. E. Baum, S. B. Ockers, B. C. English, L. Minasian, H. L. Parnes, A. W. Hsing, J. K. V. Reichardt, A. Hoque, C. M. Tangen, A. R. Kristal, I. M. Thompson and W. D. Figg: Androgen Receptor CAG Repeat Length and Association With Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. Journal of Urology, 184(6), 2297-2302 (2010)

  • [10]A. R. Kristal, D. K. Price, C. Till, J. M. Schenk, M. L. Neuhouser, S. Ockers, D. W. Lin, I. M. Thompson and W. D. Figg: Androgen Receptor CAG Repeat Length Is Not Associated With the Risk of Incident Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial. Prostate, 70(6), 584-590 (2010)

  • [11]C. Bisbal and R. H. Silverman: Diverse functions of RNase L and implications in pathology. Biochimie, 89(6-7), 789-98 (2007)

  • [12]R. H. Silverman: A scientific journey through the 2-5A/RNase L system. Cytokine Growth Factor Rev, 18(5-6), 381-8 (2007)

  • [13]J. R. Smith, D. Freije, J. D. Carpten, H. Gronberg, J. Xu, S. D. Isaacs, M. J. Brownstein, G. S. Bova, H. Guo, P. Bujnovszky, D. R. Nusskern, J. E. Damber, A. Bergh, M. Emanuelsson, O. P. Kallioniemi, J. Walker-Daniels, J. E. Bailey-Wilson, T. H. Beaty, D. A. Meyers, P. C. Walsh, F. S. Collins, J. M. Trent and W. B. Isaacs: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science, 274(5291), 1371-4 (1996)

  • [14]M. S. Meyer, K. L. Penney, J. R. Stark, F. R. Schumacher, H. D. Sesso, M. Loda, M. Fiorentino, S. Finn, R. J. Flavin, T. Kurth, A. L. Price, E. L. Giovannucci, K. Fall, M. J. Stampfer, J. Ma and L. A. Mucci: Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis, 31(9), 1597-603 (2010)

  • [15]H. Rennert, C. M. Zeigler-Johnson, K. Addya, M. J. Finley, A. H. Walker, E. Spangler, D. G. Leonard, A. Wein, S. B. Malkowicz and T. R. Rebbeck: Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev, 14(4), 949-57 (2005)

  • [16]A. Matsumoto, M. Naito, H. Itakura, S. Ikemoto, H. Asaoka, I. Hayakawa, H. Kanamori, H. Aburatani, F. Takaku, H. Suzuki, Y. Kobari, T. Miyai, K. Takahashi, E. H. Cohen, R. Wydro, D. E. Housman and T. Kodama: Human Macrophage Scavenger Receptors - Primary Structure, Expression, and Localization in Atherosclerotic Lesions. Proc Natl Acad Sci U S A, 87(23), 9133-9137 (1990)

  • [17]H. Suzuki, Y. Kurihara, M. Takeya, N. Kamada, M. Kataoka, K. Jishage, O. Ueda, H. Sakaguchi, T. Higashi, T. Suzuki, Y. Takashima, Y. Kawabe, O. Cynshi, Y. Wada, M. Honda, H. Kurihara, H. Aburatani, T. Doi, A. Matsumoto, S. Azuma, T. Noda, Y. Toyoda, H. Itakura, Y. Yazaki, S. Horiuchi, K. Takahashi, J. K. Kruijt, T. J. C. vanBerkel, U. P. Steinbrecher, S. Ishibashi, N. Maeda, S. Gordon and T. Kodama: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature, 386(6622), 292-296 (1997)

  • [18]J. Xu, S. L. Zheng, A. Komiya, J. C. Mychaleckyj, S. D. Isaacs, B. Chang, A. R. Turner, C. M. Ewing, K. E. Wiley, G. A. Hawkins, E. R. Bleecker, P. C. Walsh, D. A. Meyers and W. B. Isaacs: Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet, 72(1), 208-12 (2003)

  • [19]J. Xu, S. L. Zheng, A. Komiya, J. C. Mychaleckyj, S. D. Isaacs, J. J. Hu, D. Sterling, E. M. Lange, G. A. Hawkins, A. Turner, C. M. Ewing, D. A. Faith, J. R. Johnson, H. Suzuki, P. Bujnovszky, K. E. Wiley, A. M. DeMarzo, G. S. Bova, B. Chang, M. C. Hall, D. L. McCullough, A. W. Partin, V. S. Kassabian, J. D. Carpten, J. E. Bailey-Wilson, J. M. Trent, J. Ohar, E. R. Bleecker, P. C. Walsh, W. B. Isaacs and D. A. Meyers: Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet, 32(2), 321-5 (2002)

  • [20]D. C. Miller, S. L. Zheng, R. L. Dunn, A. V. Sarma, J. E. Montie, E. M. Lange, D. A. Meyers, J. Xu and K. A. Cooney: Germ-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men. Cancer Res, 63(13), 3486-9 (2003)

  • [21]I. Hanukoglu and Z. Hanukoglu: Stoichiometry of Mitochondrial Cytochromes-P-450, Adrenodoxin and Adrenodoxin Reductase in Adrenal-Cortex and Corpus-Luteum - Implications for Membrane Organization and Gene-Regulation. European Journal of Biochemistry, 157(1), 27-31 (1986)

  • [22]F. P. Guengerich: Cytochrome P450 and chemical toxicology. Chemical Research in Toxicology, 21(1), 70-83 (2008)

  • [23]V. Nwosu, J. Carpten, J. M. Trent and R. Sheridan: Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet, 10(20), 2313-8 (2001)

  • [24]K. A. Usmani and J. Tang: Human cytochrome P450: metabolism of testosterone by CYP3A4 and inhibition by ketoconazole. Curr Protoc Toxicol, Chapter 4, Unit4 13 (2004)

  • [25]P. L. Paris, P. A. Kupelian, J. M. Hall, T. L. Williams, H. Levin, E. A. Klein, G. Casey and J. S. Witte: Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev, 8(10), 901-5 (1999)

  • [26]C. M. Zeigler-Johnson, E. Spangler, M. Jalloh, S. M. Gueye, H. Rennert and T. R. Rebbeck: Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. Can J Urol, 15(1), 3872-82 (2008)

  • [27]D. P. BarTel: MicroRNAs: target recognition and regulatory functions. Cell, 136(2), 215-33 (2009)

  • [28]V. Ambros: The functions of animal microRNAs. Nature, 431(7006), 350-5 (2004)

  • [29]G. C. Shukla, J. Singh and S. Barik: MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol, 3(3), 83-92 (2011)

  • [30]T. W. Nilsen: Mechanisms of microRNA-mediated gene regulation in animal cells. Trends in Genetics, 23(5), 243-249 (2007)

  • [31]T. W. Nilsen: Mechanisms of microRNA-mediated gene regulation. Faseb Journal, 21(5), A92-A92 (2007)

  • [32]S. C. Theodore, J. S. Rhim, T. Turner and C. Yates: MiRNA 26a expression in a novel panel of African American prostate cancer cell lines. Ethn Dis, 20(1 Suppl 1), S1-96-100 (2010)

  • [33]G. A. Calin and C. M. Croce: MicroRNA signatures in human cancers. Nat Rev Cancer, 6(11), 857-66 (2006)

  • [34]A. Srivastava, H. Goldberger, A. Dimtchev, M. Ramalinga, J. Chijioke, C. Marian, E. K. Oermann, S. Uhm, J. S. Kim, L. N. Chen, X. Li, D. L. Berry, B. V. Kallakury, S. C. Chauhan, S. P. Collins, S. Suy and D. Kumar: MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. PLoS One, 8(10), e76994 (2013)

  • [35]B. S. Shastry: SNPs: impact on gene function and phenotype. Methods Mol Biol, 578, 3-22 (2009)

  • [36]J. Farrell, G. Petrovics, D. G. McLeod and S. Srivastava: Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci, 14(8), 15510-31 (2013)

  • [37]B. M. Ryan, A. I. Robles and C. C. Harris: Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer, 10(6), 389-402 (2010)

  • [38]S. C. Theodore, M. Davis, F. Zhao, H. Wang, D. Chen, J. Rhim, W. Dean-Colomb, T. Turner, W. Ji, G. Zeng, W. Grizzle and C. Yates: MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1. Oncotarget, 5(11), 3512-25 (2014)

  • [39]C. Preskill and J. B. Weidhaas: SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers. Crit Rev Oncog, 18(4), 327-40 (2013)

  • [40]J. A. Satia: Dietary acculturation and the nutrition transition: an overview. Appl Physiol Nutr Metab, 35(2), 219-23 (2010)

  • [41]J. C. Lo, A. K. Clark, N. Ascui, M. Frydenberg, G. P. Risbridger, R. A. Taylor and M. J. Watt: Obesity does not promote tumorigenesis of localized patient-derived prostate cancer xenografts. Oncotarget (2016)

  • [42]P. Liang, S. M. Henning, S. Schokrpur, L. Wu, N. Doan, J. Said, T. Grogan, D. Elashoff, P. Cohen and W. J. Aronson: Effect of Dietary Omega-3 Fatty Acids on Tumor-Associated Macrophages and Prostate Cancer Progression. Prostate, 76(14), 1293-302 (2016)

  • [43]P. A. Godley, M. K. Campbell, C. Miller, P. Gallagher, F. E. Martinson, J. L. Mohler and R. S. Sandler: Correlation between biomarkers of omega-3 fatty acid consumption and questionnaire data in African American and Causcasian United States males with and without prostatic carcinoma. Cancer Epidemiology Biomarkers & Prevention, 5(2), 115-119 (1996)

  • [44]R. L. Siegel, K. D. Miller and A. Jemal: Cancer statistics, 2016. CA Cancer J Clin, 66(1), 7-30 (2016)

  • [45]L. Wan, K. Pantel and Y. Kang: Tumor metastasis: moving new biological insights into the clinic. Nat Med, 19(11), 1450-64 (2013)

  • [46]M. A. Kinseth, Z. Jia, F. Rahmatpanah, A. Sawyers, M. Sutton, J. Wang-Rodriguez, D. Mercola and K. L. McGuire: Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes. Int J Cancer, 134(1), 81-91 (2014)

  • [47]D. N. Martin, B. J. Boersma, M. Yi, M. Reimers, T. M. Howe, H. G. Yfantis, Y. C. Tsai, E. H. Williams, D. H. Lee, R. M. Stephens, A. M. Weissman and S. Ambs: Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One, 4(2), e4531 (2009)

  • [48]T. A. Wallace, R. L. Prueitt, M. Yi, T. M. Howe, J. W. Gillespie, H. G. Yfantis, R. M. Stephens, N. E. Caporaso, C. A. Loffredo and S. Ambs: Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res, 68(3), 927-36 (2008)

  • [49]T. A. Wallace, D. N. Martin and S. Ambs: Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis, 32(8), 1107-1121 (2011)

  • [50]R. M. Bremnes, T. Donnem, S. Al-Saad, K. Al-Shibli, S. Andersen, R. Sirera, C. Camps, I. Marinez and L. T. Busund: The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol, 6(1), 209-17 (2011)

  • [51]L. A. Dawson, N. J. Maitland, A. J. Turner and B. A. Usmani: Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br J Cancer, 90(8), 1577-82 (2004)

  • [52]J. A. Tuxhorn, G. E. Ayala and D. R. Rowley: Reactive stroma in prostate cancer progression. J Urol, 166(6), 2472-83 (2001)

  • [53]M. Singh, R. Jha, J. Melamed, E. Shapiro, S. W. Hayward and P. Lee: Stromal Androgen Receptor in Prostate Development and Cancer. American Journal of Pathology, 184(10), 2598-2607 (2014)

  • [54]I. J. Powell and A. Bollig-Fischer: Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol, 27(6), 879-91 (2013)

  • [55]B. A. Rybicki: Epigenetics and Racial Disparities in Prostate Cancer. Springer, Dordrecht Heidelberg New York London (2013)

  • [56]B. Kwabi-Addo, S. Wang, W. Chung, J. Jelinek, S. R. Patierno, B. D. Wang, R. Andrawis, N. H. Lee, V. Apprey, J. P. Issa and M. Ittmann: Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res, 16(14), 3539-47 (2010)

  • [57]S. Majumdar, E. Buckles, J. Estrada and S. Koochekpour: Aberrant DNA methylation and prostate cancer. Curr Genomics, 12(7), 486-505 (2011)

  • [58]K. Woodson, R. Hayes, L. Wideroff, L. Villaruz and J. Tangrea: Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate, 55(3), 199-205 (2003)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Mar 2017Review

Racial disparities: disruptive genes in prostate carcinogenesis

Savita Singh 1,2, Alexis Plaga 1,2, Girish C. Shukla 1,2,*
Affiliations
Article Info

1 Department of Biological Sciences, Cleveland State University, Cleveland, Ohio, USA,

2 Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, Ohio, USA

*Author to whom correspondence should be addressed.

 

Abstract

Population specific studies in prostate cancer (PCa) reveal a unique heterogeneous etiology. Various factors, such as genetics, environment and dietary regimen seems to determine disease progression, therapeutic resistance and rate of mortality. Enormous disparity documented in disease incidences, aggressiveness and mortality in PCa among AAs (African Americans) and CAs (Caucasian Americans) is attributed to the variations in genetics, epigenetics and their association with metabolism. Scientific and clinical evidences have revealed the influence of variations in Androgen Receptor (AR), RNAse L, macrophage scavenger receptor 1 (MRS1), androgen metabolism by cytochrome P450 3A4, differential regulation of microRNAs, epigenetic alterations and diet in racial disparity in PCa incidences and mortality. Concerted efforts are needed to identify race specific prognostic markers and treatment regimen for a better management of the disease.

Keywords

  • Androgen Receptor
  • RNase L
  • Prostate Cancer
  • Cancer Disparity
  • miRNA
  • Review

References